{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:22:54Z","timestamp":1770906174126,"version":"3.50.1"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","plefa.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.plefa.2020.102220","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T20:12:26Z","timestamp":1606335146000},"page":"102220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Prostaglandins as potential targets for the treatment of polycystic kidney disease"],"prefix":"10.1016","volume":"164","author":[{"given":"Harold M.","family":"Aukema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.plefa.2020.102220_bib0001","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028191","article-title":"Ciliopathies","volume":"9","author":"Braun","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.plefa.2020.102220_bib0002","series-title":"Mol. Pathol. Clin. Pract. Ed.","first-page":"277","article-title":"Polycystic kidney disease","author":"Tan","year":"2016"},{"key":"10.1016\/j.plefa.2020.102220_bib0003","series-title":"Polycystic Kidney Disease, Autosomal Dominant","author":"Harris","year":"2018"},{"key":"10.1016\/j.plefa.2020.102220_bib0004","article-title":"Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease","author":"Lanktree","year":"2018","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1016\/j.plefa.2020.102220_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190430","article-title":"The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition","volume":"13","author":"Solazzo","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.plefa.2020.102220_bib0006","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","article-title":"Else-Kroener-Fresenius-ADPKD-Registry, Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany","volume":"28","author":"Neumann","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.plefa.2020.102220_bib0007","doi-asserted-by":"crossref","first-page":"gfw240","DOI":"10.1093\/ndt\/gfw240","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","author":"Willey","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.plefa.2020.102220_bib0008","series-title":"Canadian Institute for Health Information, Organ replacement in Canada: CORR Annual statistics, 2018","year":"2018"},{"key":"10.1016\/j.plefa.2020.102220_bib0009","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression","volume":"25","author":"Schrier","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.ajkd.2017.10.023","article-title":"Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD trials","volume":"71","author":"Brosnahan","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.plefa.2020.102220_bib0011","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.03960318","article-title":"Recent advances in the management of autosomal dominant polycystic kidney disease","author":"Chebib","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ckj\/sfx071","article-title":"Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan","volume":"11","author":"M\u00fcller","year":"2018","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.plefa.2020.102220_bib0013","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1046\/j.1523-1755.2001.00985.x","article-title":"Pain management in polycystic kidney disease","volume":"60","author":"Bajwa","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0014","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/hep.1840110619","article-title":"Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease","volume":"11","author":"Gabow","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.plefa.2020.102220_bib0015","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1681\/ASN.V1191767","article-title":"Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma","volume":"11","author":"Chauveau","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0016","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.05850518","article-title":"Vascular dysfunction, oxidative stress, and inflammation in autosomal dominant polycystic kidney disease","author":"Nowak","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0017","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0272-6386(12)80922-X","article-title":"Renal stone disease in autosomal dominant polycystic kidney disease","volume":"22","author":"Torres","year":"1993","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.plefa.2020.102220_bib0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s001470050098","article-title":"Prevalence of diverticulosis and incidence of bowel perforation after kidney transplantation in patients with polycystic kidney disease","volume":"11","author":"Dom\u00ednguez Fern\u00e1ndez","year":"1998","journal-title":"Transpl. Int."},{"key":"10.1016\/j.plefa.2020.102220_bib0019","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/STROKEAHA.110.578740","article-title":"Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease","volume":"42","author":"Xu","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.plefa.2020.102220_bib0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1474-4422(11)70109-0","article-title":"Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis","volume":"10","author":"Vlak","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.plefa.2020.102220_bib0021","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2019030298","article-title":"ALG9 Mutation carriers develop kidney and liver cysts","author":"Besse","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0022","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1084\/jem.186.11.1873","article-title":"C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent","volume":"186","author":"Trudel","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0023","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.1073\/pnas.84.23.8394","article-title":"Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease","volume":"84","author":"Cowley","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.plefa.2020.102220_bib0024","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/CIRCULATIONAHA.113.005746","article-title":"Survivin-induced abnormal ploidy contributes to cystic kidney and aneurysm formation","volume":"129","author":"Aboualaiwi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.plefa.2020.102220_bib0025","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0026","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0027","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.plefa.2020.102220_bib0028","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1242\/dev.02153","article-title":"Dysfunctional cilia lead to altered ependyma and choroid plexus function, and result in the formation of hydrocephalus","volume":"132","author":"Banizs","year":"2005","journal-title":"Development"},{"key":"10.1016\/j.plefa.2020.102220_bib0029","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.2008.111","article-title":"A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5\u2019 end of Pkd1","volume":"73","author":"Starremans","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","article-title":"Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease","volume":"30","author":"Yamaguchi","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.plefa.2020.102220_bib0031","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0032","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease","volume":"17","author":"Smith","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0033","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI64313","article-title":"Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity","volume":"122","author":"Hopp","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.plefa.2020.102220_bib0034","doi-asserted-by":"crossref","first-page":"F1622","DOI":"10.1152\/ajprenal.00036.2007","article-title":"EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells","volume":"293","author":"Elberg","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.prostaglandins.2012.03.005","article-title":"Prostaglandin E2 stimulates cystogenesis through EP4 receptor in IMCD-3 cells","volume":"98","author":"Elberg","year":"2012","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.plefa.2020.102220_bib0036","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ki.1996.445","article-title":"Chloride and fluid secretion by cultured human polycystic kidney cells","volume":"50","author":"Wallace","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0037","first-page":"F381","article-title":"Anion secretion drives fluid secretion by monolayers of cultured human polycystic cells","volume":"269","author":"Mangoo-Karim","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0038","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1681\/ASN.2006030295","article-title":"Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator\/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilation","volume":"17","author":"Magenheimer","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0039","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1172\/JCI117638","article-title":"In vitro fluid secretion by epithelium from polycystic kidneys","volume":"95","author":"Grantham","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.plefa.2020.102220_bib0040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM199307293290503","article-title":"The Secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease","volume":"329","author":"Ye","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0041","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00424-002-0880-3","article-title":"Basolateral chloride transporters in autosomal dominant polycystic kidney disease","volume":"444","author":"Lebeau","year":"2002","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.plefa.2020.102220_bib0042","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ki.1996.304","article-title":"The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro","volume":"50","author":"Davidow","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0043","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1681\/ASN.2007070828","article-title":"Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease","volume":"19","author":"Yang","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0044","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1073\/pnas.0902661107","article-title":"Mouse cystic fibrosis transmembrane conductance regulator forms cAMP-PKA-regulated apical chloride channels in cortical collecting duct","volume":"107","author":"Lu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.plefa.2020.102220_bib0045","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrm1949","article-title":"New insights into cystic fibrosis: molecular switches that regulate CFTR","volume":"7","author":"Guggino","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.plefa.2020.102220_bib0046","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ki.2008.246","article-title":"KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease","volume":"74","author":"Albaqumi","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109648","article-title":"Molecular pathways involved in injury-repair and ADPKD progression","volume":"72","author":"Formica","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.plefa.2020.102220_bib0048","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/ijms17060802","article-title":"Kidney injury molecule-1 is specifically expressed in cystically-transformed proximal tubules of the PKD\/Mhm (cy\/+) rat model of polycystic kidney disease","volume":"17","author":"Gauer","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.plefa.2020.102220_bib0049","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1046\/j.1523-1755.2001.00065.x","article-title":"Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats","volume":"60","author":"Cowley","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0050","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.2012.446","article-title":"Macrophages promote polycystic kidney disease progression","volume":"83","author":"Swenson-Fields","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0051","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0052","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1172\/JCI80467","article-title":"Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.plefa.2020.102220_bib0053","doi-asserted-by":"crossref","first-page":"F821","DOI":"10.1152\/ajprenal.00257.2006","article-title":"Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease","volume":"293","author":"Sankaran","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0054","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/nep.12045","article-title":"Role of interstitial inflammation in the pathogenesis of polycystic kidney disease","volume":"18","author":"Ta","year":"2013","journal-title":"Nephrology"},{"key":"10.1016\/j.plefa.2020.102220_bib0055","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0056","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1681\/ASN.2018010074","article-title":"Interactions between macrophages and cyst-lining epithelial cells promote kidney cyst growth in Pkd1-deficient mice","volume":"29","author":"Yang","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109649","article-title":"Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling","volume":"72","author":"Sussman","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.plefa.2020.102220_bib0058","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0962-8924(02)02294-8","article-title":"Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation","volume":"12","author":"Stork","year":"2002","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.plefa.2020.102220_bib0059","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35085068","article-title":"Transcriptional regulation by the phosphorylation-dependent factor CREB","volume":"2","author":"Mayr","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.plefa.2020.102220_bib0060","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1681\/ASN.2005060645","article-title":"Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells","volume":"17","author":"Yamaguchi","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0061","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1542\/peds.2013-3646","article-title":"Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects","volume":"134","author":"Hartung","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.plefa.2020.102220_bib0062","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00424-017-2002-2","article-title":"Regulation of renal Na-(K)-Cl cotransporters by vasopressin","volume":"469","author":"Bachmann","year":"2017","journal-title":"Pflugers Arch. Eur. J. Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0063","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","article-title":"Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease","volume":"24","author":"Gattone","year":"1999","journal-title":"Dev. Genet."},{"key":"10.1016\/j.plefa.2020.102220_bib0064","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ki.1988.2","article-title":"Renal functional changes in experimental cystic disease are tubular in origin","volume":"33","author":"Carone","year":"1988","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0065","first-page":"629","article-title":"Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease","volume":"53","author":"Seeman","year":"2004","journal-title":"Physiol. Res."},{"key":"10.1016\/j.plefa.2020.102220_bib0066","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2215\/CJN.00360110","article-title":"Early renal abnormalities in autosomal dominant polycystic kidney disease","volume":"5","author":"Meijer","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0067","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0068","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","article-title":"Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation","volume":"82","author":"Ho","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0069","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0070","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0071","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.semnephrol.2008.03.003","article-title":"Vasopressin antagonists in polycystic kidney disease","volume":"28","author":"Torres","year":"2008","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0072","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0073","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.plefa.2020.102220_bib0074","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"TEMPO 3:4 Trial investigators, tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0075","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"REPRISE Trial Investigators, tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0076","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","article-title":"Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury","volume":"349","author":"Aihara","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.plefa.2020.102220_bib0077","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0078","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0079","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12882-019-1290-5","article-title":"Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model","volume":"20","author":"Bennett","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.plefa.2020.102220_bib0080","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0081","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.plefa.2020.102220_bib0082","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.plefa.2020.102220_bib0083","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2017.08.005","article-title":"Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease","volume":"93","author":"Wang","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0084","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1681\/ASN.2015010057","article-title":"Modulation of polycystic kidney disease severity by phosphodiesterase 1 and 3 subfamilies","volume":"27","author":"Ye","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13041-014-0077-7","article-title":"Adenylyl cyclase-5 in the dorsal striatum function as a molecular switch for the generation of behavioral preferences for cue-directed food choices","volume":"7","author":"Kim","year":"2014","journal-title":"Mol. Brain."},{"key":"10.1016\/j.plefa.2020.102220_bib0086","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1007\/s12035-016-0256-x","article-title":"Loss of adenylyl cyclase type-5 in the dorsal striatum produces autistic-like behaviors","volume":"54","author":"Kim","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0087","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000166277","article-title":"Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies","volume":"17","author":"Sadana","year":"2009","journal-title":"Neurosignals"},{"key":"10.1016\/j.plefa.2020.102220_bib0088","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1097\/01.ASN.0000025282.48298.7B","article-title":"The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease","volume":"13","author":"Belibi","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0089","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2006111218","article-title":"Identification of a forskolin-like molecule in human renal cysts","volume":"18","author":"Putnam","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0090","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0091","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2009.438","article-title":"Cyclic nucleotide signaling in polycystic kidney disease","volume":"77","author":"Wang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0092","doi-asserted-by":"crossref","first-page":"F944","DOI":"10.1152\/ajprenal.00387.2010","article-title":"Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells","volume":"299","author":"Yamaguchi","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0093","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.ki.5002629","article-title":"Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy\/+ rat","volume":"73","author":"Nagao","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0094","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells11See Editorial by Torres, p. 1283.","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0095","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41598-018-20856-6","article-title":"A cleavage product of polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed","volume":"8","author":"Lin","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.plefa.2020.102220_bib0096","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00337-17","article-title":"Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease","volume":"37","author":"Ishimoto","year":"2017","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.plefa.2020.102220_bib0097","doi-asserted-by":"crossref","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","author":"Padovano","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0098","doi-asserted-by":"crossref","first-page":"F235","DOI":"10.1152\/ajprenal.00454.2004","article-title":"Prostacyclin signaling in the kidney: implications for health and disease","volume":"289","author":"Nasrallah","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0099","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/CS20050251","article-title":"Eicosanoids and renal vascular function in diseases","volume":"111","author":"Imig","year":"2006","journal-title":"Clin. Sci."},{"key":"10.1016\/j.plefa.2020.102220_bib0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.physiol.63.1.579","article-title":"G Protein\u2013coupled prostanoid receptors and the kidney","volume":"63","author":"Breyer","year":"2001","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0101","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1681\/ASN.2012020126","article-title":"PGD2-CRTH2 pathway promotes tubulointerstitial fibrosis","volume":"23","author":"Ito","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0102","doi-asserted-by":"crossref","first-page":"26586","DOI":"10.18632\/oncotarget.25005","article-title":"Prostaglandins in the pathogenesis of kidney diseases","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.plefa.2020.102220_bib0103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2017.10.006","article-title":"Physiological and pathophysiological implications of PGE 2 and the PGE 2 synthases in the kidney","volume":"134","author":"Wang","year":"2018","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.plefa.2020.102220_bib0104","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1021\/cr200085w","article-title":"Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention","volume":"111","author":"Dennis","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.plefa.2020.102220_bib0105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3945\/an.114.007732","article-title":"Advances in our understanding of oxylipins derived from dietary PUFAs","volume":"6","author":"Gabbs","year":"2015","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.plefa.2020.102220_bib0106","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jn\/125.5.1183","article-title":"Diet and disease alter phosphoinositide composition and metabolism in murine polycystic kidneys","volume":"125","author":"Aukema","year":"1995","journal-title":"J. Nutr."},{"key":"10.1016\/j.plefa.2020.102220_bib0107","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF02536384","article-title":"Abnormal lipid and fatty acid compositions of kidneys from mice with polycystic kidney disease","volume":"27","author":"Aukema","year":"1992","journal-title":"Lipids"},{"key":"10.1016\/j.plefa.2020.102220_bib0108","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1096\/fj.02-0460fje","article-title":"Alterations in renal cytosolic phospholipase A2 and cyclooxygenases in polycystic kidney disease","volume":"17","author":"Aukema","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.plefa.2020.102220_bib0109","doi-asserted-by":"crossref","first-page":"F897","DOI":"10.1152\/ajprenal.00332.2005","article-title":"Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRD- cy rat kidneys","volume":"290","author":"Warford-Woolgar","year":"2006","journal-title":"Am. J. Physiol. Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0110","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3181\/0811-RM-315","article-title":"Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease","volume":"234","author":"Peng","year":"2009","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0111","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jnutbio.2006.12.017","article-title":"COX-2 expression in cystic kidneys is dependent on dietary n-3 fatty acid composition","volume":"18","author":"Sankaran","year":"2007","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.plefa.2020.102220_bib0112","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.bbalip.2017.08.005","article-title":"Distinct oxylipin alterations in diverse models of cystic kidney diseases","volume":"1862","author":"Monirujjaman","year":"2017","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.plefa.2020.102220_bib0113","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11745-013-3859-2","article-title":"Renal cyclooxygenase products are higher and lipoxygenase products are lower in early disease in the pcy mouse model of adolescent nephronophthisis","volume":"49","author":"Yamaguchi","year":"2014","journal-title":"Lipids"},{"key":"10.1016\/j.plefa.2020.102220_bib0114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.prostaglandins.2014.10.005","article-title":"Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease","volume":"116\u2013117","author":"Ibrahim","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.plefa.2020.102220_bib0115","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1007\/s11033-012-1611-2","article-title":"Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF\/Raf\/MAPK\/ERK signaling pathway","volume":"39","author":"Xu","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.plefa.2020.102220_bib0116","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/en.2003-0903","article-title":"Regulation of cyclooxygenase expression by vasopressin in rat renal medulla","volume":"145","author":"Zhang","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.plefa.2020.102220_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.plefa.2020.102220_bib0118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146654","article-title":"Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease","volume":"11","author":"Riwanto","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.plefa.2020.102220_bib0119","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.plefa.2020.102220_bib0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5483\/BMBRep.2012.45.5.317","article-title":"Protein phosphorylation on tyrosine restores expression and glycosylation of cyclooxygenase-2 by 2-deoxy-d-glucose-caused endoplasmic reticulum stress in rabbit articular chondrocyte","volume":"45","author":"Yu","year":"2012","journal-title":"BMB Rep"},{"key":"10.1016\/j.plefa.2020.102220_bib0121","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40620-018-00578-8","article-title":"Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2WS25\/- mouse model of autosomal dominant polycystic kidney disease","volume":"32","author":"Monirujjaman","year":"2019","journal-title":"J. Nephrol."},{"key":"10.1016\/j.plefa.2020.102220_bib0122","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.plefa.2020.102220_bib0123","doi-asserted-by":"crossref","first-page":"180","DOI":"10.7150\/ijms.27719","article-title":"Nonselective cyclooxygenase inhibition retards cyst progression in a murine model of autosomal dominant polycystic kidney disease","volume":"16","author":"Zhang","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.plefa.2020.102220_bib0124","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejim.2015.03.008","article-title":"Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies","volume":"26","author":"Ungprasert","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0125","doi-asserted-by":"crossref","first-page":"e2645","DOI":"10.1097\/MD.0000000000002645","article-title":"Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury","volume":"95","author":"Chou","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.plefa.2020.102220_bib0126","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Conference participants, autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0127","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.kint.2020.02.012","article-title":"The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo","volume":"98","author":"Lannoy","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.plefa.2020.102220_bib0128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0090-6980(02)00042-4","article-title":"Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence","volume":"68\u201369","author":"Urade","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.plefa.2020.102220_bib0129","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1476-5381.1989.tb11869.x","article-title":"Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors","volume":"96","author":"Coleman","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.plefa.2020.102220_bib0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.prostaglandins.2015.04.008","article-title":"Prostacyclin receptors: transcriptional regulation and novel signalling mechanisms","volume":"121","author":"Reid","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.plefa.2020.102220_bib0131","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.marpetgeo.2011.05.006","article-title":"Impact of structural setting on diagenesis of fluvial and tidal sandstones: the Bahi Formation, Upper Cretaceous, NW Sirt Basin, North Central Libya","volume":"38","author":"Khalifa","year":"2012","journal-title":"Mar. Pet. Geol."},{"key":"10.1016\/j.plefa.2020.102220_bib0132","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/267628a0","article-title":"Effects of PGD2 on canine renal function","volume":"267","author":"Bolger","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.plefa.2020.102220_bib0133","doi-asserted-by":"crossref","first-page":"26586","DOI":"10.18632\/oncotarget.25005","article-title":"Prostaglandins in the pathogenesis of kidney diseases","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.plefa.2020.102220_bib0134","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bjp.0702393","article-title":"Prostanoid receptors involved in the relaxation of human pulmonary vessels","volume":"126","author":"Walch","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.plefa.2020.102220_bib0135","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjp.0702392","article-title":"Prostanoid receptors involved in the relaxation of human bronchial preparations","volume":"126","author":"Norel","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.plefa.2020.102220_bib0136","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/ecco-jcc\/jjw061","article-title":"Eosinophils Contribute to intestinal inflammation via chemoattractant receptor-homologous molecule expressed on Th2 Cells, CRTH2, in experimental Crohn's disease","volume":"10","author":"Radnai","year":"2016","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.plefa.2020.102220_bib0137","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4049\/jimmunol.1303484","article-title":"Opposing roles of prostaglandin D2 receptors in ulcerative colitis","volume":"193","author":"Sturm","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.plefa.2020.102220_bib0138","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jaci.2013.01.035","article-title":"Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation","volume":"131","author":"Fajt","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.plefa.2020.102220_bib0139","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-017-0777-2","article-title":"Targeting the PGD2\/CRTH2\/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives","volume":"77","author":"Kupczyk","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.plefa.2020.102220_bib0140","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/13543784.2016.1212838","article-title":"Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma","volume":"25","author":"Santus","year":"2016","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.plefa.2020.102220_bib0141","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1084\/jem.20051310","article-title":"Prostacyclin-IP signaling and prostaglandin E2-EP2\/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis","volume":"203","author":"Honda","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.plefa.2020.102220_bib0142","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0024-3205(80)90310-0","article-title":"Is prostacyclin the major pro-inflammatory prostanoid in joint fluid?","volume":"27","author":"Brodie","year":"1980","journal-title":"Life Sci"},{"key":"10.1016\/j.plefa.2020.102220_bib0143","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0014-4827(64)90311-8","article-title":"Growth and morphology of adult mouse fibroblasts under anaerobic conditions and at limiting oxygen tensionS","volume":"36","author":"CLARK","year":"1964","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.plefa.2020.102220_bib0144","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fimmu.2018.00038","article-title":"Bioactive lipids and chronic inflammation: managing the fire within","volume":"9","author":"Chiurchi\u00f9","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.plefa.2020.102220_bib0145","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1124\/jpet.106.110387","article-title":"Prostacyclin Antagonism Reduces Pain and Inflammation in Rodent Models of Hyperalgesia and Chronic Arthritis","volume":"319","author":"Pulichino","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.plefa.2020.102220_bib0146","doi-asserted-by":"crossref","first-page":"F1616","DOI":"10.1152\/ajprenal.00538.2011","article-title":"Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model","volume":"302","author":"Nasu","year":"2012","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0147","doi-asserted-by":"crossref","first-page":"PL155","DOI":"10.1016\/S0024-3205(00)00420-3","article-title":"Intrinsic prostacyclin contributes to exudation induced by bradykinin or carrageenin: a study on the paw edema induced in IP-receptor-deficient mice","volume":"66","author":"Ueno","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.plefa.2020.102220_bib0148","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0165-6147(98)01185-7","article-title":"The role of IP prostanoid receptors in inflammatory pain","volume":"19","author":"Bley","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.plefa.2020.102220_bib0149","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000045937","article-title":"Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus","volume":"87","author":"Hirawa","year":"2001","journal-title":"Nephron"},{"key":"10.1016\/j.plefa.2020.102220_bib0150","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/ndt\/gfk009","article-title":"Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats","volume":"21","author":"Ogawa","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.plefa.2020.102220_bib0151","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000076407","article-title":"Lipocalin-type prostaglandin D synthase in urine in adriamycin-induced nephropathy of mice","volume":"96","author":"Tsuchida","year":"2004","journal-title":"Nephron. Physiol."},{"key":"10.1016\/j.plefa.2020.102220_bib0152","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.biopha.2015.01.010","article-title":"Role of cyclooxygenase-2 in the development of interstitial fibrosis in kidneys following unilateral ureteral obstruction in mice","volume":"70","author":"Kamata","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.plefa.2020.102220_bib0153","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1194\/jlr.M082362","article-title":"Bone marrow-derived cPLA2\u03b1 contributes to renal fibrosis progression","volume":"59","author":"Montford","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plefa.2020.102220_bib0154","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejphar.2013.07.032","article-title":"Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5\/6 nephrectomized chronic kidney disease rats","volume":"714","author":"Yamaguchi","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.plefa.2020.102220_bib0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.prostaglandins.2014.06.001","article-title":"A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis","volume":"112","author":"Goto","year":"2014","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.plefa.2020.102220_bib0156","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0014-2999(02)01988-X","article-title":"Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model","volume":"449","author":"Yamada","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.plefa.2020.102220_bib0157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1690474","article-title":"The protective effect of beraprost sodium on diabetic nephropathy by inhibiting inflammation and p38 MAPK signaling pathway in high-fat diet\/streptozotocin-induced diabetic rats","volume":"2016","author":"Peng","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.plefa.2020.102220_bib0158","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12882-015-0130-5","article-title":"Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial","volume":"16","author":"Koyama","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.plefa.2020.102220_bib0159","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1054\/plef.2001.0315","article-title":"PGI2analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency","volume":"65","author":"Fujita","year":"2001","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids."}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327820301782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327820301782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:09:37Z","timestamp":1760602177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952327820301782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":159,"alternative-id":["S0952327820301782"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2020.102220","relation":{},"ISSN":["0952-3278"],"issn-type":[{"value":"0952-3278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostaglandins as potential targets for the treatment of polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins, Leukotrienes and Essential Fatty Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plefa.2020.102220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102220"}}